[The combined estrogen-gestagen treatment of metastasizing mammary carcinoma using with SH 834].
D000328:Adult; D000367:Age Factors; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001859:Bone Neoplasms / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury; D004958:Estradiol / Q000009:adverse effects / Q000627:therapeutic use*; D004971:Estrus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007565:Jaundice / Q000209:etiology; D008113:Liver Neoplasms / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008593:Menopause; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010997:Pleural Neoplasms / Q000188:drug therapy*; D011247:Pregnancy; D011374:Progesterone / Q000009:adverse effects / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000209:etiology
D011374:Progesterone; D004958:Estradiol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase
Die Ostrogen-Gestagen-Kombinationsbehandlung des metastasierenden Mammakarzinoms mit SH 834.